LLY Q4 Deep Dive: Obesity Medicines, Pipeline Progress, and Market Expansion Drive Outperformance

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year revenue guidance of $81.5 billion at the midpoint came in 4.8% above analysts’ estimates. Its non-GAAP profit of $7.54 per share was 8.7% above analysts’ consensus estimates.

Is now the time to buy LLY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong contribution from Mounjaro and Zepbound, noting that volume growth in these products was the primary driver of revenue gains. CEO David Ricks underscored the impact of new product launches and expanded manufacturing capacity, stating, “We delivered robust revenue growth, advanced our pipeline, expanded our manufacturing footprint, and helped over 70 million people around the world.” The company also benefited from progress in its neuroscience and immunology segments, with Kisanlo becoming the US market leader in amyloid-targeting therapies and solid adoption trends for Eblis and Omvo.

Looking forward, Eli Lilly’s guidance reflects management’s expectation of continued high demand for its obesity portfolio, further bolstered by anticipated regulatory approvals and broader market access. CFO Lucas Montarce cited the launch of oral GLP-1 therapy orforglipron and expanded Medicare coverage for obesity medicines as key drivers of projected growth, while also acknowledging pricing pressures from new reimbursement agreements and competition. Management expressed confidence in maintaining industry-leading volume growth, with Ricks noting, “We expect revenue to be driven by key products, partially offset by lower realized prices as we expand access and increase volumes globally.”

Key Insights from Management’s Remarks

Management attributed the quarter’s results to exceptional demand for incretin-based therapies, new product launches, and strategic expansion in international markets, while also investing heavily in R&D and manufacturing.

• Incretin portfolio momentum: Sales of Mounjaro and Zepbound surged as both products expanded their market leadership in type 2 diabetes and obesity treatment, with robust prescription growth in the US and strong uptake in new international markets.
• New product launches: The company successfully launched Inlureo and secured new indications for Omvo and Jayperca, supporting top-line growth and diversifying its product mix beyond the incretin class.
• Pipeline advancement: Eli Lilly initiated 14 new phase three programs and now has 36 active phase three trials, including late-stage candidates in obesity, oncology, immunology, and neuroscience, reflecting a significant investment in future innovation.
• Manufacturing expansion: Ongoing investments in new manufacturing sites in the US and Europe increased production capacity, enabling the company to meet rising demand for obesity medicines and support global launches.
• Business development activity: Management completed 39 business development transactions, adding multiple clinical-stage assets across therapeutic areas and announcing a major collaboration with NVIDIA to accelerate drug discovery using artificial intelligence.

Drivers of Future Performance

Eli Lilly’s outlook is shaped by the expansion of its obesity portfolio, new launches, and anticipated broader access through regulatory and reimbursement milestones.

• Obesity medicine market expansion: Management expects continued volume growth from Zepbound, Mounjaro, and the upcoming launch of orforglipron, with Medicare coverage set to drive broader adoption and a growing out-of-pocket market for obesity treatments.
• Pipeline-driven diversification: The company plans to launch new medicines in immunology, oncology, and neuroscience, and anticipates that products such as Eblis, Jayperca, Inlureo, and Kisanlo will contribute to revenue growth while offsetting expected declines from late lifecycle drugs.
• Pricing and reimbursement headwinds: Management acknowledged that price erosion, driven by new government agreements, direct-to-patient pricing, and China’s National Reimbursement Drug List, will partially offset volume gains, but believes these will be outweighed by increased access and patient reach.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely monitor (1) the pace and scale of the orforglipron launch in the US and initial international approvals, (2) the rollout and patient uptake of Medicare-covered obesity medicines, and (3) continued progress in late-stage pipeline readouts across obesity, immunology, and oncology. Manufacturing execution and the success of new business development initiatives will also serve as important indicators of future performance.

Eli Lilly currently trades at $1,104, up from $1,003 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.